NCT04193267

Brief Summary

The purpose of this study is to investigate the feasibility of using repetitive transcranial magnetic stimulation (rTMS) - a form of non-invasive brain stimulation - to improve language functioning in individuals who have the logopenic variant of primary progressive aphasia (PPA-L) - a slowly progressive impairment of language, characterized by difficulties with word-finding, sentence repetition and sentence comprehension.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2020

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 18, 2019

Completed
22 days until next milestone

First Posted

Study publicly available on registry

December 10, 2019

Completed
6 months until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2022

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2022

Completed
Last Updated

March 22, 2021

Status Verified

March 1, 2021

Enrollment Period

2.2 years

First QC Date

November 18, 2019

Last Update Submit

March 19, 2021

Conditions

Keywords

Primary Progressive AphasiaBrain Stimulation

Outcome Measures

Primary Outcomes (1)

  • Change in score on the Druks and Masterson Naming Task

    Assessment of change in language function as a result of rTMS intervention. Minimum score = 0. Maximum score = 24. Higher scores indicate better naming performance.

    One week pre- and one week post-rTMS treatment

Study Arms (1)

Repetitive Transcranial Magnetic Stimulation (rTMS)

EXPERIMENTAL

30 sessions of high-frequency (10Hz) repetitive stimulation applied over the posterior region of the left superior temporal gyrus in patients with logopenic primary progressive aphasia (PPA-L) using a MagStim Rapid2 Transcranial Magnetic Simulation machine.

Device: MagStim Rapid2 Transcranial Magnetic Simulation

Interventions

A non-invasive method of brain stimulation

Repetitive Transcranial Magnetic Stimulation (rTMS)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of PPA-L (confirmed by a neurologist or neuropsychiatrist who has observed the patient for at least one year);
  • Mild to moderate language impairment as assessed by the Druks and Masterson Naming Task;
  • Native English speaker.

You may not qualify if:

  • Cerebrovascular disorders, hydrocephalus or intra-cranial mass, documented by MRI;
  • History of traumatic brain injury, seizures, or another neurological disease;
  • Significant medical problems (e.g. poorly controlled diabetes or hypertension or cancer within the past 5 years);
  • Major depressive disorder, bipolar disorder, schizophrenia, substance use disorder or mental retardation according to the criteria of the DSM-IV;
  • Any contraindication for rTMS (e.g., implanted metal devices; cardiac pacemaker or pacemaker wires; neurostimulators; implanted pumps, metal in the body \[rods, plates, screws, shrapnel, dentures, IUD\] or metallic particles in the body, surgical clips in the head, previous neurosurgery, cochlear implants, prosthetic heart valves);
  • Currently pregnant or breastfeeding.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Boniface Hospital

Winnipeg, Manitoba, R2H2A6, Canada

RECRUITING

MeSH Terms

Conditions

Aphasia, Primary Progressive

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesAphasiaSpeech DisordersLanguage DisordersCommunication DisordersNeurobehavioral ManifestationsNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental Disorders

Study Officials

  • Michelle Tsang, MD

    University of Manitoba

    PRINCIPAL INVESTIGATOR
  • Mandana Modirrousta, MD PhD

    University of Manitoba

    STUDY DIRECTOR

Central Study Contacts

Benjamin Meek

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 18, 2019

First Posted

December 10, 2019

Study Start

June 1, 2020

Primary Completion

August 1, 2022

Study Completion

December 1, 2022

Last Updated

March 22, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations